Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Qianlie Shule Granules** is an approved oral traditional Chinese medicine granule product developed and manufactured by Dongguan Jinmeiji Pharmaceutical for benign prostatic conditions and urinary tract disorders. Based on the company pipeline information provided, it is a marketed Chinese medicine formulation described in traditional-use terms as supporting kidney tonification and relieving blood stasis, with symptomatic use in prostate-related and urinary complaints. No specific modern molecular target or pharmacologically validated single-target mechanism was identified from the available source material; the product appears to be positioned as a proprietary sugar-free TCM granule formulation included in medical insurance and local essential medicine coverage in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qianlie Shule Granules.